Document Detail

Reduced acute toxicity associated with the use of volumetric modulated arc therapy for the treatment of adenocarcinoma of the prostate.
MedLine Citation:
PMID:  24674413     Owner:  NLM     Status:  In-Data-Review    
PURPOSE: Novel techniques to deliver intensity modulated radiation therapy (IMRT) have resulted in improved treatment efficiency and dosimetric endpoints. We aimed to compare acute gastrointestinal (GI) and genitourinary (GU) toxicity in patients treated for adenocarcinoma of the prostate (ACP) using volumetric modulated arc therapy (VMAT).
METHODS AND MATERIALS: A total of 122 (71 IMRT and 51 VMAT) ACP patients treated from 2004 to 2011 with definitive external beam radiation therapy were analyzed. Dose-volume histogram endpoints (V40, V65, V70, and V75 of the bladder and rectum) were collected for each patient. Median follow-up for patients treated with VMAT was 269 days versus IMRT was 1121 days. Acute Common Toxicity Criteria for Adverse Events (CTCAE) GI and GU toxicity scores, obtained during each weekly treatment check, were compared across cohorts. The univariate (UV) association between the covariates and outcomes was assessed and multivariable (MV) cumulative logit models were fit for each outcome.
RESULTS: Median patient age was 68 years and median prostate-specific antigen was 8.3. Both bladder and rectal V40, V65, V70, and V75 were all higher in the IMRT group versus the VMAT group (P < .05), which was likely influenced by larger planning target volumes in the IMRT group. The VMAT group had significantly lower rates of acute GU and acute GI CTCAE toxicity on UV association analysis. On MV analysis, VMAT remained independently associated with acute GU (odds ratio [OR], 0.18; 95% confidence interval [CI], 0.07-0.44; P < .001) and GI (OR, 0.16; 95% CI, 0.07-0.41; P < .001) toxicity.
CONCLUSIONS: VMAT appears to be independently associated with lower rates of acute GI and GU toxicity when compared with traditional IMRT. Further exploration of toxicity improvements associated with VMAT use in the definitive treatment of ACP is needed.
William A Hall; Lauren Colbert; Dana Nickleach; Joseph Shelton; David M Marcus; Jeffrey Switchenko; Peter J Rossi; Karen Godette; Sherrie Cooper; Ashesh B Jani
Related Documents :
8601973 - Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic...
24482383 - Coronary artery bypass grafting-related bleeding complications in real-life acute coron...
7729633 - Double-blind trial of omeprazole and amoxicillin to cure helicobacter pylori infection ...
Publication Detail:
Type:  Journal Article     Date:  2013-02-21
Journal Detail:
Title:  Practical radiation oncology     Volume:  3     ISSN:  1879-8500     ISO Abbreviation:  Pract Radiat Oncol     Publication Date:    2013 Oct-Dec
Date Detail:
Created Date:  2014-03-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101558279     Medline TA:  Pract Radiat Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e157-64     Citation Subset:  -    
Copyright Information:
Copyright © 2013 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcino...
Next Document:  National study to determine the comfort levels of radiation therapists and medical dosimetrists to r...